NCT01823081View on ClinicalTrials.gov

Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema

PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

December 31, 2015

Conditions
Diabetic Macular Edema
Interventions
DRUG

Intravitreal injection of bevacizumab (Avastin)

DRUG

Intravitreal injection of fasudil and bevacizumab (Avastin)

intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)

Trial Locations (1)

Unknown

Tehran

All Listed Sponsors
lead

Shahid Beheshti University of Medical Sciences

OTHER

NCT01823081 - Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema | Biotech Hunter | Biotech Hunter